📰 Linerx Ltd News
Linerx Ltd News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Linerx Ltd. Real-time updates on events, politics, business and more.
May 30, 2024
BioLineRx Ltd. (NASDAQ:BLRX – Get Free Report) was the recipient of a large decrease in short interest in May. As of May 15th, there was short interest totalling 219,100 shares, a decrease of 46.6% from the April 30th total of 410,600 shares. Based on an average daily volume of 410,600 shares, the short-interest ratio is […]
April 27, 2024
StockNews.com upgraded shares of BioLineRx (NASDAQ:BLRX – Free Report) to a sell rating in a report published on Tuesday morning. Separately, HC Wainwright reissued a buy rating and issued a $21.00 price objective on shares of BioLineRx in a research note on Wednesday, April 17th. View Our Latest Analysis on BioLineRx BioLineRx Stock Performance NASDAQ:BLRX […]
April 25, 2024
BioLineRx (NASDAQ:BLRX – Get Free Report) was upgraded by investment analysts at StockNews.com to a “sell” rating in a research report issued to clients and investors on Tuesday. Separately, HC Wainwright reiterated a “buy” rating and set a $21.00 price target on shares of BioLineRx in a report on Wednesday, April 17th. Check Out Our […]
April 25, 2024
BioLineRx (NASDAQ:BLRX – Get Free Report) was upgraded by equities research analysts at StockNews.com to a “sell” rating in a research report issued on Tuesday. Separately, HC Wainwright restated a “buy” rating and set a $21.00 target price on shares of BioLineRx in a research note on Wednesday, April 17th. Check Out Our Latest Report […]
March 29, 2024
HC Wainwright reaffirmed their buy rating on shares of BioLineRx (NASDAQ:BLRX – Free Report) in a research report report published on Tuesday morning, Benzinga reports. HC Wainwright currently has a $21.00 price target on the biotechnology company’s stock. HC Wainwright also issued estimates for BioLineRx’s Q1 2024 earnings at ($0.29) EPS, Q2 2024 earnings at […]
March 27, 2024
HC Wainwright reiterated their buy rating on shares of BioLineRx (NASDAQ:BLRX – Free Report) in a report issued on Tuesday, Benzinga reports. They currently have a $21.00 price target on the biotechnology company’s stock. Separately, StockNews.com upgraded shares of BioLineRx to a sell rating in a report on Monday, December 4th. View Our Latest Research […]
January 14, 2024
BioLineRx Ltd. (NASDAQ:BLRX – Get Free Report) was the target of a large growth in short interest in the month of December. As of December 31st, there was short interest totalling 225,200 shares, a growth of 96.2% from the December 15th total of 114,800 shares. Based on an average daily volume of 349,200 shares, the […]
January 3, 2024
BioLineRx (NASDAQ:BLRX – Get Free Report) and Sonnet BioTherapeutics (NASDAQ:SONN – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, risk, earnings, valuation and analyst recommendations. Valuation & Earnings This table compares BioLineRx and […]
January 3, 2024
BioLineRx (NASDAQ:BLRX – Get Free Report) and Sonnet BioTherapeutics (NASDAQ:SONN – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, profitability, valuation and dividends. Analyst Recommendations This is a summary of recent […]
December 5, 2023
BioLineRx (NASDAQ:BLRX – Get Free Report) was upgraded by investment analysts at StockNews.com to a “sell” rating in a research report issued on Monday. Separately, HC Wainwright restated a “buy” rating and set a $21.00 price objective on shares of BioLineRx in a research report on Monday, November 20th. Check Out Our Latest Analysis on […]